Alexander Koers
St Thomas' Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Alexander Koers.
Journal of Clinical Investigation | 2013
Panagiotis Karagiannis; Amy E. Gilbert; Debra H. Josephs; Niwa Ali; Tihomir Dodev; Louise Saul; Isabel Correa; Luke Roberts; Emma Beddowes; Alexander Koers; Carl Hobbs; Silvia Ferreira Rodrigues Mendes Ferreira; Jenny Geh; Ciaran Healy; Mark Harries; K. Acland; Philip J. Blower; Tracey J. Mitchell; David J. Fear; James Spicer; Katie E. Lacy; Frank O. Nestle; Sophia N. Karagiannis
Host-induced antibodies and their contributions to cancer inflammation are largely unexplored. IgG4 subclass antibodies are present in IL-10–driven Th2 immune responses in some inflammatory conditions. Since Th2-biased inflammation is a hallmark of tumor microenvironments, we investigated the presence and functional implications of IgG4 in malignant melanoma. Consistent with Th2 inflammation, CD22+ B cells and IgG4+-infiltrating cells accumulated in tumors, and IL-10, IL-4, and tumor-reactive IgG4 were expressed in situ. When compared with B cells from patient lymph nodes and blood, tumor-associated B cells were polarized to produce IgG4. Secreted B cells increased VEGF and IgG4, and tumor cells enhanced IL-10 secretion in cocultures. Unlike IgG1, an engineered tumor antigen-specific IgG4 was ineffective in triggering effector cell–mediated tumor killing in vitro. Antigen-specific and nonspecific IgG4 inhibited IgG1-mediated tumoricidal functions. IgG4 blockade was mediated through reduction of FcγRI activation. Additionally, IgG4 significantly impaired the potency of tumoricidal IgG1 in a human melanoma xenograft mouse model. Furthermore, serum IgG4 was inversely correlated with patient survival. These findings suggest that IgG4 promoted by tumor-induced Th2-biased inflammation may restrict effector cell functions against tumors, providing a previously unexplored aspect of tumor-induced immune escape and a basis for biomarker development and patient-specific therapeutic approaches.
Chemical Communications | 2011
David J. Berry; Yongmin Ma; James R. Ballinger; Richard Tavaré; Alexander Koers; Kavitha Sunassee; Tao Zhou; Saima Nawaz; Gregory Mullen; Robert C. Hider; Philip J. Blower
A new tripodal tris(hydroxypyridinone) bifunctional chelator for gallium allows easy production of (68)Ga-labelled proteins rapidly under mild conditions in high yields at exceptionally high specific activity and low concentration.
Cancer Immunology, Immunotherapy | 2012
Sophia N. Karagiannis; Debra H. Josephs; Panagiotis Karagiannis; Amy E. Gilbert; Louise Saul; Sarah Rudman; Tihomir Dodev; Alexander Koers; Philip J. Blower; Christopher Corrigan; Andrew J. Beavil; James Spicer; Frank O. Nestle; Hannah J. Gould
Therapeutic antibodies have revolutionised treatment of some cancers and improved prognosis for many patients. Over half of those available are approved for haematological malignancies, but efficacious antibodies for solid tumours are still urgently needed. Clinically available antibodies belong to the IgG class, the most prevalent antibody class in human blood, while other classes have not been extensively considered. We hypothesised that the unique properties of IgE, a class of tissue-resident antibodies commonly associated with allergies, which can trigger powerful immune responses through strong affinity for their particular receptors on effector cells, could be employed for passive immunotherapy of solid tumours such as ovarian and breast carcinomas. Our laboratory has examined this concept by evaluating two chimaeric antibodies of the same specificity (MOv18) but different isotype, an IgG1 and an IgE against the tumour antigen folate receptor α (FRα). The latter demonstrates the potency of IgE to mount superior immune responses against tumours in disease-relevant models. We identified Fcε receptor-expressing cells, monocytes/macrophages and eosinophils, activated by MOv18 IgE to kill tumour cells by mechanisms such as ADCC and ADCP. We also applied this notion to a marketed therapeutic, the humanised IgG1 antibody trastuzumab and engineered an IgE counterpart, which retained the functions of trastuzumab in restricting proliferation of HER2/neu-expressing tumour cells but also activated effector cells to kill tumour cells by different mechanisms. On-going efficacy, safety evaluations and future first-in-man clinical studies of IgE therapeutics constitute key metrics for this concept, providing new scope for antibody immunotherapies for solid tumours.
Clinical & Experimental Allergy | 2011
Sarah Rudman; Debra H. Josephs; H. Cambrook; Panagiotis Karagiannis; Amy E. Gilbert; Tihomir Dodev; John F. Hunt; Alexander Koers; Ana Montes; Leonie S. Taams; Silvana Canevari; Mariangela Figini; Philip J. Blower; Andrew J. Beavil; C. F. Nicodemus; Christopher Corrigan; Stan B. Kaye; Frank O. Nestle; Hannah J. Gould; James Spicer; Sophia N. Karagiannis
Background IgE antibodies, sequestered into tissues and retained locally by the high‐affinity IgE receptor, FcɛRI, on powerful effector cells such as mast cells, macrophages and eosinophils, may offer improvements in the therapy of solid tumours. The chimeric antibody, MOv18 IgE, against the human ovarian carcinoma antigen, folate receptor α (FRα), is more effective than its IgG1 counterpart in xenograft models of ovarian cancer. Although MOv18 IgE binds to a single epitope on FRα and cannot cross‐link IgE receptors on basophils, there remains a risk that components in the circulation of ovarian cancer patients might cross‐link FRα‐MOv18‐IgE‐receptor‐FcɛRI complexes on basophils to cause type I hypersensitivity.
PLOS ONE | 2011
Ehsan Sharif-Paghaleh; Kavitha Sunassee; Richard Tavaré; Kulachelvy Ratnasothy; Alexander Koers; Niwa Ali; Rowa Alhabbab; Philip J. Blower; Robert I. Lechler; Lesley A. Smyth; Gregory Mullen; Giovanna Lombardi
Regulatory T cells (Tregs) were identified several years ago and are key in controlling autoimmune diseases and limiting immune responses to foreign antigens, including alloantigens. In vivo imaging techniques including intravital microscopy as well as whole body imaging using bioluminescence probes have contributed to the understanding of in vivo Treg function, their mechanisms of action and target cells. Imaging of the human sodium/iodide symporter via Single Photon Emission Computed Tomography (SPECT) has been used to image various cell types in vivo. It has several advantages over the aforementioned imaging techniques including high sensitivity, it allows non-invasive whole body studies of viable cell migration and localisation of cells over time and lastly it may offer the possibility to be translated to the clinic. This study addresses whether SPECT/CT imaging can be used to visualise the migratory pattern of Tregs in vivo. Treg lines derived from CD4+CD25+FoxP3+ cells were retrovirally transduced with a construct encoding for the human Sodium Iodide Symporter (NIS) and the fluorescent protein mCherry and stimulated with autologous DCs. NIS expressing self-specific Tregs were specifically radiolabelled in vitro with Technetium-99m pertechnetate (99mTcO4 −) and exposure of these cells to radioactivity did not affect cell viability, phenotype or function. In addition adoptively transferred Treg-NIS cells were imaged in vivo in C57BL/6 (BL/6) mice by SPECT/CT using 99mTcO4 −. After 24 hours NIS expressing Tregs were observed in the spleen and their localisation was further confirmed by organ biodistribution studies and flow cytometry analysis. The data presented here suggests that SPECT/CT imaging can be utilised in preclinical imaging studies of adoptively transferred Tregs without affecting Treg function and viability thereby allowing longitudinal studies within disease models.
British Journal of Dermatology | 2012
Panagiotis Karagiannis; Amy E. Gilbert; Tihomir Dodev; Debra H. Josephs; Nura Alkathiri; Dimitra Dafou; Chrysanthi Ainali; Alexander Koers; Louise Saul; Sophia Tsoka; James Spicer; Hannah J. Gould; Andrew J. Beavil; Frank O. Nestle; Sophia N. Karagiannis
Bioscience, University Sydney, AUPhotoaged skin is characterised by profound remodelling of the extracellular matrix (ECM). We have previously shown that UV chromophore (Cys, His, Phe, Trp and Tyr)-rich proteins are differentially degraded by UV radiation (UVR). We tested the hypothesises that; (i) UV-mediated ECM degradation occurs via reactive oxygen species (ROS), by exposing chromophore-rich fibronectin and chromophore-poor tropoelastin to UVR in depleted-O2 and D2O environments and (ii) exogenous ROS mediates differential degradation of the same proteins. As the photodynamic production of ROS can be inhibited in depleted-O2 environments we exposed purified fibronectin to a broadband UVB (TL-12: 50 and 500mJ/cm2) in ambient and depleted-O2 conditions by bubbling with N2. Solutions were analysed by reducing SDS-PAGE. Irradiation of fibronectin in ambient-O2 (50 and 500mJ/cm2) caused dose-dependent aggregation (5 and 83 fold changes in the optical density (OD) of the aggregate at 50 and 500mJ/cm2 respectively), fibronectin aggregation was abrogated (68 fold lower OD) in the depleted-O2 compared with ambient-O2. Conversely, fibronectin aggregation was increased 4 fold in D2O compared with H2O environments. UV-mediated changes to the molecular weight (Mw) of fibronectin were recapitulated by exposure to H2O2 (40mM for 2 hrs). In contrast, UVB irradiation in both H2O and D2O had no observable effect on the Mw of tropoelastin. Therefore, ROS may play an important role in the selective degradation of long-lived UV chromophore-rich ECM in both UV-exposed and protected ageing tissues. Research supported by Alliance Boots.
Archive | 2011
Sarah Rudman; Debra H. Josephs; H. Cambrook; Panos Karagiannis; Amy E. Gilbert; Tihomir Dodev; John F. Hunt; Alexander Koers; Antonio Montes; Leonie S. Taams; Silvana Canevari; Michela Figini; Philip J. Blower; Andrew J. Beavil; C. F. Nicodemus; Christopher Corrigan; Stanley B. Kaye; Frank O. Nestle; Hannah J. Gould; James Spicer; Sophia N. Karagiannis
Cancer Research | 2018
Matthew Kraman; Natalie Fosh; Katarzyna Kmiecik; Katy Everett; Carlo Zimarino; Mustapha Faroudi; Mateusz Wydro; Alexander Koers; Lesley Young; Daniel Gliddon; Michelle Morrow; Jacqueline Doody; Mihriban Tuna; Neil Brewis
Cancer Research | 2013
Sophia N. Karagiannis; Debra H. Josephs; Panagiotis Karagiannis; Louise Saul; Amy E. Gilbert; Tihomir Dodev; Alexander Koers; Philip J. Blower; Andrew J. Beavil; Frank O. Nestle
Archive | 2012
Panagiotis Karagiannis; Amy E. Gilbert; Tihomir Dodev; Debra H. Josephs; Niwa Ali; Dimitra Dafou; Chrysanthi Ainali; Alexander Koers; Sophia Tsoka; Stanley B. Kaye; James Spicer; Andrew J. Beavil; Frank O. Nestle; Sophia N. Karagiannis